15,646 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Natural Investments LLC

Natural Investments LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 15,646 shares of the company’s stock, valued at approximately $1,345,000.

A number of other institutional investors have also modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $404,910,000. Amundi raised its position in Novo Nordisk A/S by 26.4% during the 4th quarter. Amundi now owns 3,311,456 shares of the company’s stock worth $283,615,000 after buying an additional 692,567 shares during the last quarter. DAVENPORT & Co LLC raised its position in Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after buying an additional 451,641 shares during the last quarter. Wellington Management Group LLP purchased a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $42,017,000. Finally, DSM Capital Partners LLC increased its holdings in shares of Novo Nordisk A/S by 16.7% during the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock valued at $172,678,000 after purchasing an additional 286,912 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Down 9.5 %

Shares of NVO opened at $78.87 on Tuesday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market cap of $353.91 billion, a P/E ratio of 23.97, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The company’s 50-day moving average price is $84.77 and its 200 day moving average price is $104.45. Novo Nordisk A/S has a 12-month low of $77.55 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.